- GSK took advantage of ASCO dip to get discount on NuvalentGSK’s $10.6 billion buyout of Nuvalent, announced Tuesday, was the largest in the company’s history. But did new CEO Luke Miels get a discount? At $124 a share, the price Miels paid ...Endpoints · 1mo ago↗ source
- Novo's M&A leader leaves for Forbion; Perrigo CEO's 'personal conduct' issues led to resignationForbion’s portfolio companies have been no stranger to M&A deals in recent years. But the Dutch investment firm now wants more of its biotechs to benefit from the industry’s ...Endpoints · 1mo ago↗ source
- Sciwind has two Western partners for its obesity drug, but is open to moreSciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet. The Chinese biotech is seeking new partners for the ri…